Bibliografia

Boey D. et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49, 1360–1370 (2006).

Carruba M., [intervista a] Professore di Farmacologia all'Università degli Studi di Milano e Presidente della Società Italiana dell’Obesità 16/07/2007. Consultata il 12/10/2007. http://it.health.yahoo.net/p_special.asp?id=16136&s=14&c=39

Després J.P. and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444, 881-887 (2006).

Drucker D. J. The biology of incretin hormones. Cell Metab. 3, 153–165 (2006).

Ferrannini E. and Iozzo P. Is insulin resistance atherogenic? A review of the evidence. Atheroscler. Suppl. 7, 5–10 (2006).

Gesta S., Tseng Y-H., and Khan C.R. Developmental Origin of Fat: Tracking Obesity to Its Source. Cell 131, October 19 (2007).

Guarente L. Sirtuins as potential target for metabolic syndrome. Nature 444, 868-874 (2006).

Hirosumi J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333–336 (2002).

Hotamisligil G. S. et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271, 665–668 (1996).

Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).

Kahn S.E., Hull R.L and Utzschneider K.M. Mechanism linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840-846 (2006).

Katsuura G., Asakawa A. and Inui A. Roles of pancreatic polypeptide in regulation of food intake. Peptides 23, 323–329 (2002) .

Kojima M. and Kangawa K. Ghrelin: structure and function. Physiol. Rev. 85, 495–522 (2005).

Konstantinides S. et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J. Clin. Invest. 108, 1533–1540 (2001).

Kuo L.E. et al. (2007). Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nature Medicine 13, 803 – 811

McGavock J. M. et al. Adiposity of the heart, revisited. Ann. Intern. Med. 144, 517–524 (2006).

Milne J.C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716 (2007).

Miyawaki K. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Med. 8, 738–742 (2002).

Murphy K.G. and Bloom S.R. Gut hormones and the regulation of energy homeostasis. Nature 444, 854-859 (2006).

Ozcan U. et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457–461 (2004).

Ratner R. et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp. Clin. Endocrinol. Diabetes 113, 199–204 (2005).

Richa Saxena et al. Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels. Science Vol. 316. no. 5829, pp. 1331 – 1336 (2007).

Robbins. Le basi patologiche delle malattie. Sesta edizione. Piccin (2000).

Rosen E.D. and Spiegelman B.M. Adipocytes as regulator of energy balance and glucose homeostasis. Nature 444, 847-853 (2006).

Smith S. R. and Wilson P. W. Free fatty acids and atherosclerosis — guilty or innocent? J. Clin. Endocrinol. Metab.91, 2506–2508 (2006).

Van der Lely A.J., Tschop M., Heiman M.L. and Ghigo E. Biological, physiological, phatophysiological, and pharmacological aspects of ghrelin. Endocrine Rev, 25(3): 426-457 (2005).

Van Gaal L.F., Mertens I.L. and De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880 (2006).

Weisberg S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808 (2003).

West D. B. et al. Infusion of cholecystokinin between meals into free-feeding rats fails to prolong the intermeal interval. Physiol. Behav. 39, 111–115 (1987).

Wynne K. et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54, 2390–2395 (2005).

Yildiz B.O et al. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A. 101(28): 10434–10439 (2004).

Zhou Y. T. et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl Acad. Sci. USA 97, 1784–1789 (2000).

Zorrilla E. P. et al. Vaccination against weight gain. Proc. Natl Acad. Sci. USA (2006).

.........................................................................................................................
per citare questa rassegna:
Buonsanti G. (2008) Obesità: un'epidemia silenziosa, [http://www.biomedit.it/speciali/obesita]